Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27875557 | 0.89 | MAPT (0.44) | MAPTMAPK1KDM4EGAARECQL | |
| SCHEMBL2422616 | 0.86 | MAPT (0.45) | MAPTMAPK1KDM4EGAARECQL | |
| SCHEMBL2424704 | 0.86 | MAPT (0.45) | MAPTMAPK1KDM4EGAARECQL | |
| SCHEMBL21377196 | 0.86 | MAPT (0.48) | MAPTMAPK1KDM4EGAARECQL | |
| SCHEMBL508428 | 0.86 | MAPT (0.45) | MAPTMAPK1KDM4EGAARECQL | |
| SCHEMBL5549267 | 0.85 | MAPT (0.44) | MAPTMAPK1KDM4EGAARECQL | |
| SCHEMBL2424125 | 0.84 | MAPT (0.44) | MAPTMAPK1KDM4EGAARECQL | |
| SCHEMBL2425009 | 0.83 | MAPT (0.43) | MAPTMAPK1KDM4EGAARECQL | |
| SCHEMBL28605125 | 0.82 | MAPT (0.41) | MAPTMAPK1KDM4EGAARECQL | |
| SCHEMBL2430111 | 0.82 | GCGR (0.47) | MAPTMAPK1KDM4EGAAKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | disclosed |
| EP-2459571-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | Global Alliance For Tb Drug Development (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011014774-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | NOX5, MT-ND5, NQO1 | MAPT 1533/4885MAPK1 3399/4885KDM4E 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.